# Novartis AG (NVS) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/NVS
## Company Profile
- Ticker: NVS
- Exchange: NYSE
- Sector: Biopharma, Novel Therapies, Gene Therapy
- Location: Switzerland
- Tags: Novel Therapies, Gene Therapy, Oncology, Immunology
## Stock Data
- Close: 154.61 USD
- Market cap: 273773035138.19998 USD
- Last updated: 2026-08-11
## Business Overview
Novartis is a global medicines company with major exposure to innovative therapies across oncology, immunology, neuroscience, and cardiovascular disease. The company has been reshaping its portfolio around higher-growth, innovation-driven products.
## Why The Stock Is Moving

As of Aug 11, 2026, NVS closed down 1.39% at $154.61. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in Switzerland and listed on NYSE as an ADR, Novartis is a global biopharma with strong European and U.S. exposure. Its profile is defined by global commercial scale and a high-quality pipeline.

## Business Model

Novartis generates value through branded medicines, launches, and pipeline reinvestment. Investors follow earnings quality, launch cadence, and whether the company can continue replacing mature products with growth assets.

## Landscape Position

Novartis sits among the most important global pharma names because it combines scale with consistent innovation. It is less volatile than clinical-stage biotech, but pipeline and regulatory updates can still shift the story.

## Future Catalysts

- Novartis should be tracked for Fabhalta expansion, remibrutinib progress, and any late-stage update that keeps the growth mix shifting away from older franchises. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.

## Recent News
- 2007-04-12 05:52 EST — [Novartis Completes Its Business Portfolio Restructuring, Divesting Gerber for US$5.5 Billion to Nestle](https://biopharmsignal.com/news/NVS/novartis-completes-its-business-portfolio-restructuring-divesting-gerber-for-us--9efcf2c6) — Source: Novartis AG
- 2006-09-29 05:10 EST — [Novartis Announces Initiative to Improve Access to State-of-the-Art Anti-Malarial Treatment Coartem](https://biopharmsignal.com/news/NVS/novartis-announces-initiative-to-improve-access-to-state-of-the-art-anti-malaria-f237893a) — Source: Novartis AG
- 2006-05-04 14:41 EST — [Novartis Awarded Up to USD220 Million by U.S. Department of Health and Human Services for Development of Cell Culture-Derived Influenza Vaccine](https://biopharmsignal.com/news/NVS/novartis-awarded-up-to-usd220-million-by-u-s-department-of-health-and-human-serv-ba7a30e4) — Source: Novartis AG
- 2006-04-24 06:48 EST — [Novartis Delivers Strong Start to 2006 in First Quarter with Excellent Sales and Earnings Growth Performance](https://biopharmsignal.com/news/NVS/novartis-delivers-strong-start-to-2006-in-first-quarter-with-excellent-sales-and-b358e7bd) — Source: Novartis AG
- 2006-04-20 05:44 EST — [New Drug Application for Rasilez, an Innovative Oral Renin Inhibitor to Treat High Blood Pressure, Accepted for U.S. Regulatory Review](https://biopharmsignal.com/news/NVS/new-drug-application-for-rasilez-an-innovative-oral-renin-inhibitor-to-treat-hig-28bff87f) — Source: Novartis AG